Evidence map›Paper›PMID 41711097›Full record

ArticleMolecular oncology2026

Circular RNA expression landscapes in myelodysplastic neoplasms: Associations with mutational signatures and disease progression.

Eileen Wedge, Morten Tulstrup, Gabriele Todisco, Pedro Moura, Christophe Côme, Jakob Werner Hansen, Jakob Schmidt Jespersen, Balthasar Schlotmann, Maria Creignou, Mette Dahl and 8 more

Abstract read
In one paragraph

Article in Molecular oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors.

Eileen WedgeDepartment of Hematology, Rigshospitalet, Copenhagen University Hospital, Denmark.ORCID https://orcid.org/0000-0003-3756-6094
Morten TulstrupDepartment of Hematology, Rigshospitalet, Copenhagen University Hospital, Denmark.
Gabriele TodiscoDivision of Hematology, Department of Medicine, Karolinska University Hospital, Stockholm, Sweden.
Pedro MouraDivision of Hematology, Department of Medicine, Karolinska University Hospital, Stockholm, Sweden.ORCID https://orcid.org/0000-0002-0493-5394
Christophe CômeDepartment of Hematology, Rigshospitalet, Copenhagen University Hospital, Denmark.
Jakob Werner HansenDepartment of Hematology, Rigshospitalet, Copenhagen University Hospital, Denmark.
Jakob Schmidt JespersenBiotech Research and Innovation Center (BRIC), University of Copenhagen, Denmark.ORCID https://orcid.org/0000-0002-4930-5900
Balthasar SchlotmannBiotech Research and Innovation Center (BRIC), University of Copenhagen, Denmark.
Maria CreignouDivision of Hematology, Department of Medicine, Karolinska University Hospital, Stockholm, Sweden.
Mette DahlDepartment of Hematology, Rigshospitalet, Copenhagen University Hospital, Denmark.
Claudia SchöllkopfDepartment of Hematology, Rigshospitalet, Copenhagen University Hospital, Denmark.
Klas Raaschou-JensenDepartment of Hematology, Odense University Hospital, Denmark.
Krister WennerbergBiotech Research and Innovation Center (BRIC), University of Copenhagen, Denmark.ORCID https://orcid.org/0000-0002-1352-4220
Bo PorseBiotech Research and Innovation Center (BRIC), University of Copenhagen, Denmark.
Joachim WeischenfeldtBiotech Research and Innovation Center (BRIC), University of Copenhagen, Denmark.
Eva Hellström-LindbergDivision of Hematology, Department of Medicine, Karolinska University Hospital, Stockholm, Sweden.
Lasse Sommer KristensenDepartment of Biomedicine, Aarhus University, Denmark.
Kirsten GrønbækDepartment of Hematology, Rigshospitalet, Copenhagen University Hospital, Denmark.

Funding

Kræftens Bekæmpelse R223-A13071Kræftens Bekæmpelse R364-A21357Lundbeck Foundation R307-2018-3433Novo Nordisk Fonden NNF17CC0027852
6 · The paper itself

Abstract

Myelodysplastic neoplasms (MDS) are heterogeneous malignancies originating in hematopoietic stem cells. In this explorative study, we carried out ultra-deep total RNA sequencing on FACS-sorted CD34+ bone marrow cells from 71 patients and eight healthy age-matched controls. We investigated the expression of circular RNAs (circRNAs), a group of noncoding RNAs produced by back-splicing of nonadjacent splice sites. Key findings were further explored in an independent cohort of 118 patients with MDS and ring sideroblasts. circRNA abundance was higher in the disease groups than in controls, and different spliceosome mutations were associated with distinct circRNA expression patterns. Expression of the proliferation-related gene MKI67 was negatively correlated with circRNA abundance. High circRNA abundance was associated with a significantly increased risk of disease progression at 3 years. The majority of the 38 circRNAs that were significantly upregulated in MDS demonstrated highly correlated expression, and many were associated with risk of leukemic progression. Furthermore, we confirmed the specificity of circZEB1 expression to cases with SF3B1 mutations. We conclude that aberrant circRNA expression is found in MDS and displays associations with disease characteristics and patient outcomes.

Indexed as

circular RNAmyelodysplastic neoplasianon‐coding RNARNA sequnecing

Identifiers

PMID41711097
PMCPMC13399211

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.